The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Immune-Related Pneumonitis: Recognition and Management

Checkpoint inhibitor lung toxicity requiring prompt intervention

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Immune-Related Pneumonitis: Recognition and Management?

Immune-related pneumonitis is inflammation of lung parenchyma triggered by immune checkpoint inhibitor activation of T-cell responses against shared self-antigens.

Incidence varies by drug class with higher rates with anti-PD-1, lower with anti-PD-L1 and increased risk with combination immunotherapy.

Median onset is 2 to 6 months after starting therapy, but pneumonitis can occur at any time including after discontinuation.

Radiographic patterns include cryptogenic organizing pneumonia, ground glass opacities, interstitial pneumonitis, hypersensitivity pneumonitis-like or acute respiratory distress patterns.

Severity is graded 1 to 4 based on symptoms, oxygenation and need for hospitalization.

Symptoms

New or worsening dyspnea with progressive shortness of breath at rest or exertion.
Persistent cough that may be dry or minimally productive.
Chest pain, often pleuritic in nature, can occur.
Fever, fatigue and decreased exercise tolerance accompany respiratory symptoms in many patients.
Asymptomatic radiologic findings on routine surveillance imaging are increasingly recognized.

Risk Factors

Combination immunotherapy with anti-CTLA-4 and anti-PD-1 increases risk substantially.
Pre-existing lung disease including chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis or interstitial lung disease.
Prior thoracic radiation therapy and lung surgery.
Smoking history and lung cancer as primary diagnosis.
Cancer type with increased rates noted in non-small cell lung cancer and renal cell carcinoma.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • New or worsening dyspnea, persistent cough or fever during checkpoint inhibitor therapy requires urgent evaluation.
  • Severe shortness of breath, chest pain, hypoxia or signs of respiratory failure necessitate emergency assessment.
  • Progression of symptoms despite initial corticosteroid therapy indicates need for treatment intensification.
  • Suspicion of superimposed infection with productive cough, fever or imaging changes warrants comprehensive workup.
  • Long-term follow-up after pneumonitis recovery is essential to monitor for recurrence and pulmonary function.

Treatment Methods

01
Grade 1 with asymptomatic radiologic findings may warrant continued therapy with close monitoring or treatment hold.
02
Grade 2 with mild symptoms requires holding immunotherapy and starting prednisone 1 mg/kg/day with consideration of resumption upon resolution.
03
Grade 3 or 4 with severe symptoms or hypoxia requires permanent discontinuation, hospitalization, methylprednisolone 1 to 2 mg/kg/day intravenously and consideration of additional immunosuppression.
04
Refractory cases may need infliximab, mycophenolate mofetil, intravenous immunoglobulin or cyclophosphamide.
05
Bronchoscopy with bronchoalveolar lavage may be needed to exclude infection; antibiotic prophylaxis during prolonged steroids and gradual taper over 6 to 8 weeks with close monitoring complete management.

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.